Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).